Selected Publications
Freyer CW, Carulli A, Frey NV, Gill SI, Hexner EO, Martin ME, Luger SM, Porter DL, Stadtmauer EA, Loren AW: Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation Leuk Lymphoma : 2024.
Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Appelbaum FR, Erba HP: A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML Leukemia : 2024.
Sung AD, Koll T, Gier SH, Racioppi A, White G, Lew M, Free M, Agarwal P, Bohannon LM, Johnson EJ, Selvan B, Babushok DV, Frey NV, Gill SI, Hexner EO, Martin M, Perl AE, Pratz KW, Luger SM, Chao NJ, Fisher AL, Stadtmauer EA, Porter DL, Loren AW, Bhatt VR, Gimotty PA, McCurdy SR: Pre-Conditioning Frailty Phenotypes Influence Survival and Relapse for Older Allogeneic Transplantation Recipients Transplant Cell Ther : 2024.
Woyach JA, Perez Burbano GE, Ruppert AS, Miller CR, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly JS, Nattam S, Larson RA, Erba HP, Litzow MR, Luger SM, Owen C, Kuzma C, Abramson JS, Little RF, Dinner SN, Stone RM, Uy GL, Stock W, Mandrekar SJ, Byrd JC: Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL Blood : 2024.
Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Appelbaum FR, Erba HP.: A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia : 2023.
Altman JK, Zuckerman T, Koprivnikar J, McCloskey J, Kota V, Keng M, Frankfurt O, Abaza Y, Bixby D, Emadi A, Burch M, Bhatnagar B, Luger SM, Percival MM, Wolach O, Craig M, Ganzel C, Roboz GJ, Levi I, Gourevitch A, Flaishon L, Tessler S, Blomberg C, Gengrinovitch S Dr, Ben Yakar R, Rowe JM: Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study Blood Adv : 2023.
Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW: Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia Am J Hematol : 2023.
Chippendale L, Freyer CW, Carulli A, Babushok DV, Frey NV, Gill SI, Hexner EO, Luger SM, Martin ME, Porter DL, Stadtmauer EA, Loren AW: One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant J Oncol Pharm Pract : 2023.
Neumann B, Onken J, König N, Stetefeld H, Luger S, Luger AL, Schlachetzki F, Linker R, Hau P, Bumes E: Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysi J Neurooncol : 2023.
Foran JM, Sun Z, Lai C, Fernandez HF, Cripe LD, Ketterling RP, Racevskis J, Luger SM, Paietta E, Lazarus HM, Zhang Y, Bennett JM, Levine RL, Rowe JM, Litzow MR, Tallman MS: Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis. Cancer : 2023.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-157
34th and Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-614-1847
Patient appointments: 800-789-7366